All In Biotech

Drug Trial Radar · NCT06708156

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Progression of Myopia in Children and Adolescents in a Randomized, Double-blind, Placebo Parallel-controlled, Multicenter, Phase III Clinical Trial

Last checked: Nov 20, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

606

Planned (sponsor's estimate)

Start

Jun 15, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Oupushifang Pharmaceutical Technology Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Seefunge Pharmaceutical Technology Co., Ltd.; AUTEK China Inc.
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial aims to test the effectiveness and safety of two low-dose atropine sulfate eye drops for delaying myopia progression in children and adolescents. Primary Objective: evaluate the effectiveness of 0.01% and 0.02% atropine sulfate eye drops for 96 weeks compared to placebo in delaying myopia progression in children and adolescents. Secondary Objective: evaluate the safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) in delaying myopia progression in children and adolescents. Exploratory Objective: 1. the efficacy and safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) for 144 weeks. 2. evaluate the rebound effect of two low-concentration atropine sulfate eye drops (0.01%/0.02%) after discontinuation.

Conditions

  • Myopia
  • Myopia Progression

Interventions

  • Atropine sulfate eye drops 0.01%Drug

    Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

  • Atropine sulfate eye drops 0.02%Drug

    Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

  • Placebo eye dropsDrug

    Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effective change from baseline in equivalent spherical refraction at Week 96 visitTime frame: At the Week 96 visit

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital Affiliated to Capital Medical University

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • Chongqing Aier Eye Hospital

    Chongqing, China · Recruiting

  • Shanghai Eye Disease Prevention and Treatment Center (Shanghai Eye Hospital)

    Shanghai, China · Recruiting

  • Tianjin Medical University Eye Hospital

    Tianjin, China · Recruiting

  • Hefei Maternal and Child Health Hospital

    Hefei, Anhui, China · Recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Xuancheng People's Hospital

    Xuancheng, Anhui, China · Recruiting

  • The Second Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Recruiting

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • The First People's Hospital of Zunyi

    Zunyi, Guizhou, China · Recruiting

  • Daqingshi People's Hospital

    Daqing, Heilongjiang, China · Recruiting

  • Kaifeng Central Hospital

    Kaifeng, Henan, China · Recruiting

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China · Recruiting

  • Huai'an First People's Hospital

    Huai'an, Jiangsu, China · Recruiting

  • Affiliated Eye Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Weifang Eye Hospital

    Weifang, Shandong, China · Recruiting

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China · Recruiting

  • Shanxi Eye Hospital

    Taiyuan, Shanxi, China · Recruiting

  • Xianyang Hospital of Yan'an University

    Xianyang, Shanxi, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.